Bioenvision: Suvus decreases hepatitis C viral load up to 92%

By Elaine Rigoli

Tampa, Fla., Sept. 8 - Bioenvision, Inc. said results of a randomized phase 2 trial of Suvus in patients with chronic hepatitis C virus infection suggested that patients receiving 50 days of Suvus treatment showed a mean percentage decrease of 83% and in patients receiving 100 days of Suvus treatment, the median viral load showed a mean percentage decrease of 92%.

The New York pharmaceutical company said the results are particularly significant considering that most of the patients had failed prior therapy and had cirrhosis of the liver.

Bioenvision has filed for marketing authorization in Egypt, noting that an estimated 7 to 8 million people in Egypt are infected with hepatitis C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.